Two-business structure comprising prescription pharmaceuticals and consumer healthcare
First written in FY2016. 20 of 21 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2023RestatedAnnual report
「As we conduct our business primarily in prescription pharmaceuticals and OTC pharmaceuticals, our reportable segments are the Prescription Pharmaceuticals Business and the Consumer Healthcare Business.」
The company continues to operate with a two-business structure whose principal reportable segments are the Prescription Pharmaceuticals Business and Consumer Healthcare Business. - FY2023-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2023-Q1RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2022-Q3RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2022-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2022-Q1RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2020RestatedAnnual report
「As we conduct our business primarily in prescription pharmaceuticals and OTC pharmaceuticals, our reportable segments are the Prescription Pharmaceuticals Business and the Consumer Healthcare Business.」
The company continues to operate with a business structure comprising two principal reportable segments. - FY2020-Q3RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be classified and disclosed as the principal reportable segments. - FY2020-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2020-Q1RestatedAnnual report
「The operating results by segment are as follows: ① Prescription Pharmaceuticals Business ② Consumer Healthcare Business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2019RestatedAnnual report
「As we conduct our business primarily in prescription pharmaceuticals and OTC pharmaceuticals, our reportable segments are the Prescription Pharmaceuticals Business and the Consumer Healthcare Business.」
The company continues to operate with a business structure comprising two principal reportable segments. - FY2019-Q3RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2019-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2019-Q1RestatedAnnual report
「The operating results by segment are as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as reportable segments. - FY2018-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as the principal reportable segments. - FY2017RestatedAnnual report
「As we conduct our business primarily in prescription pharmaceuticals and OTC pharmaceuticals, our reportable segments are the Prescription Pharmaceuticals Business and the Consumer Healthcare Business.」
The company continues to operate with the Prescription Pharmaceuticals Business and Consumer Healthcare Business as its principal reportable segments. - FY2017-Q3RestatedAnnual report
「Information on the amounts of sales and profit or loss for each reportable segment」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as reportable segments. - FY2017-Q2RestatedAnnual report
「Information on the amounts of sales and profit or loss for each reportable segment」
The Prescription Pharmaceuticals Business and Consumer Healthcare Business continue to be disclosed as reportable segments. - FY2017-Q1RestatedAnnual report
「From the first quarter of the current consolidated fiscal year, we changed the method of classifying the company’s results into the Prescription Pharmaceuticals Business and Consumer Healthcare Business reportable segments.」
Although the method of allocating the Vietnamese subsidiary’s results changed, the core reportable segments remain the same two businesses. - FY2016First statedAnnual report
「Our reportable segments are the Prescription Pharmaceuticals Business and the Consumer Healthcare Business.」
Although other businesses are included, the two core reportable segments are these businesses.